Today, on October 10 – on the World Mental Health Day – JSC Grindeks organizes an international conference “Modern Ambulatory Health Care Methods in Psychiatry”. The conference is organized in order to associate with the global health protection activities, pay attention to the mental health problems and contribute to its improvement.
The leading specialists in the field of psychiatry from Latvia, Russia, Ukraine, Belarus, Kazakhstan, Georgia, Moldova, Azerbaijan and Uzbekistan will participate in the conference and present their reports.
Chairman of the board of Grindeks Jānis Romanovskis emphasizes: “ We keep observing continuously the tendencies on pharmaceutical market, responding to them quickly and actively to offer consumers new medicines necessary to meet their needs. At the same time, we are aware of the importance of successful dialogue with medical professionals allowing to find out the needs of healthcare professionals and patients, as well as exchange the latest information, studies and experience.”
Research and development activities of Grindeks are focused on the fulfilment of the yet unachieved pharmaceutical needs. According to statistical data of the World Health organization, 6.9% of population in the world suffer from different central nervous system diseases, besides the amount of these diseases has a tendency to grow by 6 – 11% Annually. Upon assessing these tendencies, development and production of the medicines that affect the central nervous system is set as one of strategic directions of the Grindeks. Currently, there are 12 products in Grindeks product portfolio for treatment of neurological and psychic diseases – both, for treatment of depression, neuroses, insomnia and anxiety conditions, as well as parkinsonism, schizophrenia and other diseases.
Overview of JSC Grindeks
JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main activity is research, development, production and sales of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
A range of Grindeks products covers a successful combination of original products and generics. It includes the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics.
The holding company of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia. It has representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and CIS countries, Japan, the USA. JSC Grindeks shares are listed in the Official List of Riga Stock Exchange.
Contacts:
Ilze Kreicmane
JSC Grindeks Public Relations Specialist
Phone: (+371) 67083336, (+371) 26466681
fax: (+371) 67083505
E-mail: [email protected]
